Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
about
Use of metformin in the setting of mild-to-moderate renal insufficiencyMetformin for obesity or overweightMetformin for obesity or overweightUse of metformin in diseases of agingMetformin: Current knowledgeSomething old, something new and something very old: drugs for treating type 2 diabetesManagement of diabetic kidney disease: Recent advancesMetformin in obesity, cancer and aging: addressing controversiesThe management of type 2 diabetic patients with hypoglycaemic agentsOptimal therapy of type 2 diabetes: a controversial challengeAdverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis.Preadmission metformin use and mortality among intensive care patients with diabetes: a cohort study.Hyperglycemia in the intensive care unit: is insulin the only option?Changes in metformin use in chronic kidney disease.Metformin in peritoneal dialysis: a pilot experienceMetformin ameliorates the Phenotype Transition of Peritoneal Mesothelial Cells and Peritoneal Fibrosis via a modulation of Oxidative Stress.Systematic review of methods used in meta-analyses where a primary outcome is an adverse or unintended eventMechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo.Cardiovascular impact of drugs used in the treatment of diabetesDiabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes.Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes.Diabetes medication use and blood lactate level among participants with type 2 diabetes: the atherosclerosis risk in communities carotid MRI studyMetformin-induced lactic acidosis with emphasis on the anion gap.Clinical management of concurrent diabetes and tuberculosis and the implications for patient servicesMetformin-associated lactic acidosis: predisposing factors and outcomeMetformin-associated lactic acidosisUse of Metformin in Patients with Kidney and Cardiovascular Diseases.Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized PatientsManagement of Hyperglycemia in Diabetic Kidney Disease.Phaeochromocytoma presenting with pseudo-intestinal obstruction and lactic acidosis.Impact of metformin use on the prognostic value of lactate in sepsis.Metformin and phenethyl isothiocyanate combined treatment in vitro is cytotoxic to ovarian cancer cultures.Metformin in non-diabetic patients presenting with ST elevation myocardial infarction: rationale and design of the glycometabolic intervention as adjunct to primary percutaneous intervention in ST elevation myocardial infarction (GIPS)-III trialPrevalence of Metformin Use and the Associated Risk of Metabolic Acidosis in US Diabetic Adults With CKD: A National Cross-Sectional Study.Metformin and its clinical use: new insights for an old drug in clinical practice.Metformin-associated lactic acidosis (MALA): case files of the Einstein Medical Center medical toxicology fellowshipMetformin: an old but still the best treatment for type 2 diabetes.Treatment Approach to Patients With Severe Insulin Resistance.Induction of AMPK activity corrects early pathophysiological alterations in the subtotal nephrectomy model of chronic kidney disease.Prescribing attitudes, behaviors and opinions regarding metformin for patients with diabetes: a focus group study.
P2860
Q22241290-4EC25BA6-5BD0-4592-9C34-DE8792F3B2DAQ24195145-78287E78-48AD-46BA-8DEC-E968FB5F5B19Q24236796-CB777E7B-3631-425D-AFB8-709CB6680779Q26828760-4913040A-1554-4BEC-97A0-1DF395429279Q26853666-0A7CFBD2-AF3E-48CC-8DC0-462A1DF838A9Q26865663-3CCD328A-1EB3-4306-AEAA-109484ED0299Q27009775-A8178841-1373-4B6B-9760-B67D6F1699AEQ28480735-F4622B59-3FBA-46DB-975E-E292B998713CQ30417363-A3CD25C8-4845-41BA-87EA-C17DF676CF20Q33577712-8BF27B88-DD68-4D70-B1EE-B70EDD01C9ABQ33587839-0F41B060-8953-44D3-BCED-250B4F063AB0Q33754815-453D00DD-553F-4CFB-BEF9-9745C2074F6DQ33762250-5349D1FE-1ABF-4BF9-867B-C336D141810DQ33783138-DC45E504-08A7-4839-9285-69A4422BAC4CQ33837650-978AABB8-FC3C-4ECB-8646-21AD7360F99CQ33915937-1CBCBE48-6EDB-45DB-8443-F9747EF30581Q34254787-2524264A-AC91-4412-ABF6-583760FE64A1Q34257480-6EE01BFF-24E7-4E44-9C64-CBD0AEFD8E91Q34383575-D4F221F8-7643-4FCE-9575-5AC5215C6612Q34429278-4A693DF2-647D-486D-A6C2-FF1E6A0C0DBDQ34446161-5B601CB4-7AA1-4EF3-A716-DD8525FDB7FFQ34540104-D85296EF-4BAE-4730-BCD8-31DD8F8192E7Q34689007-C4244D4A-CBEE-4D65-83A0-3BFB1E54F224Q35240921-56A6FB9D-1D80-4E42-A235-047AD31FB6F6Q35260863-CF5773ED-4960-42D1-9F6A-533D60834C07Q35260892-23A5A9BC-926E-49AA-B46B-99353026F525Q35688570-B4A5EB44-8F1B-4529-8958-E73C51D9075AQ35912987-B55D9AA5-66C4-43F0-93D9-D5B687F31C69Q35953856-4875443A-B779-44A4-9A75-1617D57A984CQ35983269-ED562822-001B-4949-8D8D-C226FE5A5CC6Q36049464-7E327D84-2771-4CAE-B373-D9EF3F8F0681Q36226632-A5F52A62-F405-4EF2-AD7D-D2364C4E1C28Q36297833-944F95F8-2DA4-4BE8-B7F4-6113A1388678Q36420975-0112776D-FD79-42EB-8695-756C12DC4BF1Q36423076-CC1C600C-4393-4E1C-ADBB-0019B59A7BFDQ36621860-DE1F438B-60F3-4823-8449-3C6954B4D6C0Q36715464-B9F1D00D-9F7E-4C27-B27D-5C59B1A556C5Q36803134-E6FF4DE0-48AD-4853-A53A-605EE35A6C19Q37142481-2D9519C8-4AC7-4B19-9F85-02475B0BD9E7Q37196371-B44E19A8-C39C-4E86-8B42-CEEECA245A40
P2860
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
@en
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
@en-gb
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
@nl
type
label
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
@en
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
@en-gb
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
@nl
prefLabel
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
@en
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
@en-gb
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
@nl
P2093
P2860
P1476
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
@en
P2093
Edwin E Salpeter (posthumous)
Elizabeth Greyber
Gary A Pasternak
Shelley R Salpeter
P2860
P356
10.1002/14651858.CD002967.PUB3
P577
2010-01-20T00:00:00Z